Stocks / NPCE
NeuroPace Inc's 10-K, read.
Bob rates NeuroPace Inc (NPCE) 36/100, lean bearish, on the 10-K filed March 3, 2026, updated through the 10-Q filed November 12, 2026.
NeuroPace has a differentiated, reimbursed epilepsy device with growing RNS System revenue and a narrowing net loss, but its cash is shrinking, its equity has fallen to about $11.5 million, and it carries about $60 million of high-cost secured debt with liquidity covenants that are already tight. The recovery case depends on meeting the $90.0 million 2026 RNS System revenue condition in its covenants and reaching self-funding before that cushion runs out.
- Liquidity covenant pressure: cash, equivalents and short-term investments were $49.2 million at September 30, 2026, below the $60.0 million Applicable Liquidity Threshold that applies until June 30, 2027. The company says it is in compliance with all covenants. When liquidity is below the threshold, a trailing 12-month RNS System revenue minimum of $73.7 million applies, and trailing revenue was $89.5 million. The lower $35.0 million threshold depends on earning at least $90.0 million of RNS System revenue in 2026.
- Cash burn and shrinking reserves: operating cash use was $12.6 million for the first nine months of 2026, up from $11.5 million a year earlier, and cash plus short-term investments fell from about $61 million at year-end 2025.
- Thin equity base: total stockholders' equity dropped to $11.5 million at September 30, 2026, from $19.0 million at December 31, 2025, against an accumulated deficit of $568.6 million.
- Going-concern language: the 10-Q says management believes cash will fund operations for at least 12 months, but it also says covenant failure could accelerate the debt and raise doubt about the company's ability to continue as a going concern.
- Expensive, secured debt: the MidCap term loan (about $60 million principal) carries a 10.8% effective rate, roughly $4.6 million of interest expense in the first nine months of 2026, and a $61.2 million principal-plus-exit-fee repayment due in 2030. The loan is secured by substantially all company assets.
Not investment advice — general research, the same for every reader. You make your own calls.
Want the full read?
Run NPCE in Bob for the live meter, or go deep with five years of filings behind it.
Read NPCE in Bob →Last read November 14, 2026. Bob's Research is a financial publisher, not an investment adviser. Everything here is general research and education — not personalized advice, and not a recommendation to buy or sell any security. Ratings are the same for every reader. You make your own calls.